Neurodegenerative (ND) complications in Langerhans cell histiocytosis (LCH) are a late-onset but dramatic sequelae for which incidence and risk factors are not well defined. Based on a national prospective registry of paediatric LCH patients, we determined the incidence rate of clinical ND LCH (cND-LCH) and analysed risk factors, taking into account disease extent and molecular characteristics. Among 1897 LCH patients, 36 (1Á9%) were diagnosed with a cND-LCH. The 10-year cumulative incidence of cND-LCH was 4Á1%. cND-LCH typically affected patients previously treated for a multisystem, risk organ-negative LCH, represented in 69Á4% of cND-LCH cases. Pituitary gland, skin and base skull/orbit bone lesions were more frequent (P < 0Á001) in cND-LCH patients compared to those without cND-LCH (respectively 86Á1% vs. 12Á2%, 75Á0% vs. 34Á2%, and 63Á9% vs. 28Á4%). The 'cND susceptible patients' (n = 671) i.e., children who had experienced LCH disease with pituitary or skull base or orbit bone involvement, had a 10-year cND risk of 7Á8% vs. 0% for patients who did not meet these criteria. Finally, BRAF V600E status added important information among these cND susceptible patients, with the 10-year cND risk of 33Á1% if a BRAF V600E mutation was present compared to 2Á9% if it was absent (P = 0Á002).
Langerhans cell histiocytosis (LCH) is characterized by inflammatory lesions containing abundant CD1a+ CD207+ histiocytes that lead to the destruction of affected tissues. This disease most commonly affects children (Egeler et al, 2010) , and half of cases involve the BRAF V600E somatic mutation (H eritier et al, 2016) . Recent advances in the molecular understanding of LCH have provided opportunities to optimize and personalize treatment through improved risk stratification, targeted therapy and assessment of therapy response (Berres et al, 2015; H eritier et al, 2015 . Central nervous system (CNS) involvement in LCH can be subdivided into two subtypes, with different clinical and radiological patterns, each corresponding with a distinct pathophysiology. First, the tumorous CNS subtype presents as unique or multiple contrast-enhancing space-occupying mass lesions, which can be located anywhere in the CNS but is most commonly found in the hypothalamic-pituitary region. These lesions exhibit the typical histopathological pattern of active LCH lesions (infiltration by CD1a+ CD207+ histiocytes) and usually respond to vinblastine-steroid combined therapy or cladribine monotherapy (Grois et al, 2010) .
In the second subtype, neurodegenerative (ND) LCH lesions mainly affect the cerebellum and brain stem (Ribeiro et al, 2008) . Pathological reports of ND-LCH are scarce. In these lesions, neuronal and axonal degeneration and secondary myelin loss are observed but CD1a+ histiocytes are always missing. Interestingly, in some cases inflammatory lesions were present, dominated by CD8+ lymphocytes suggesting that the progressive clinical neurological symptoms may be a secondary neurodegenerative process (Grois et al, 2005) .
The causes of ND lesions are not understood. Predominately, neurological symptoms are cerebellar ataxia, cognitive disorders, motor involvement and pseudobulbar palsy, all of which are responsible for severe disability. Magnetic resonance imaging (MRI) shows signal changes in white and deep grey matter, with cortical atrophy (Grois et al, 2010) . Although significant efforts have been made to better define the criteria pattern (Nanduri et al, 2003; Grois et al, 2005; Martin-Duverneuil et al, 2006; Prosch et al, 2007; Imashuku et al, 2008; Wnorowski et al, 2008; Le Guennec et al, 2014) , ND-LCH remains a difficult issue. Despite progress in the management of active LCH lesions, the prevalence of ND-LCH has not decreased (Rigaud et al, 2016) . The wide range of its estimated prevalence, ranging from 1 to 24% (The French Langerhans' Cell Histiocytosis Study Group, 1996; Haupt et al, 2004; Mittheisz et al, 2007; Wnorowski et al, 2008; Laurencikas et al, 2011) , is based on studies with small sample sizes and recruitment process bias. To date, the only identified risk factor for ND-LCH is diabetes insipidus (DI) secondary to pituitary lesions (Donadieu et al, 2004; Haupt et al, 2004; Grois et al, 2006) , although other risk factors have been previously suggested, such as craniofacial bone lesions or chronic/reactivating LCH disease, but without direct statistical evidence (Grois et al, 2010) . Finally, no treatment has shown efficacy in preventing neurological deterioration in ND-LCH.
Recently, Mass et al (2017) showed in a mouse model that expression of BRAF V600E somatic mosaicism in microglia results in a severe late-onset neurodegenerative disorder, with shared features observed in ND-LCH. In this model, BRAF inhibitor showed efficacy, especially when initiated early (Mass et al, 2017) . The identification of a risk group is essential for developing a preventive or early curative strategy. This need prompted us to evaluate a large cohort of children with LCH to determine the correlations between clinical ND-LCH and the clinical and molecular characteristics of LCH.
Patients and methods

Patients
Patients were children or young adults (age <18 years at diagnosis) with a biopsy-proven diagnosis of LCH according to Histiocyte Society criteria who were included in the French LCH registry (1983 . Clinical ND (cND)-LCH was defined as development of symptoms of neurological dysfunction as previously described (cerebellar ataxia, pyramidal tract involvement, neuropsychological impairment, pseudobulbar palsy) (Nanduri et al, 2003; Wnorowski et al, 2008; Le Guennec et al, 2014) , together with detection of characteristic brain MRI patterns in the cerebellar, brainstem, and/ or cerebral white matter and cerebellar dentate nuclei, basal ganglia, and/or brainstem deep grey matter (Martin-Duverneuil et al, 2006) . The age-appropriate Wechsler Intelligence Scales were used to assess neuropsychological impairment: the Wechsler Preschool and Primary Scale of Intelligence-Revised (WPPSI-R; Wechsler, 1989) for children younger than 6 years, the Wechsler Intelligence Scale for Children-IV (WICS-IV; Wechsler, 2003) for children aged 6 years to 17 years, and the Wechsler Adult Intelligence-IV Scale (WAIS-IV; Wechsler, 2008) from the age of 17 years. Psychiatric disorders were defined based on the DSM-IV classification (American Psychiatric Association, 2000) .
The demographic data, type of treatments, clinical characteristics and extent of disease were recorded according to the classifications established by the Histiocyte Society (Haupt et al, 2013) . Patients were classified considering the number of organs (or systems) involved, and risk organ (RO) involvement. The relevant ROs were the liver, spleen and haematological system.
The four classifications were as follows: SS, single system, i.e., one organ, and no lung or RO involvement; MS ROÀ, multiple organs involved but no lung or RO involvement; Lung+, lung involvement isolated or in combination with another organ except RO involvement; and RO+ MS, involvement of at least one RO. Bone localizations involved, among others, the head bones, which included skull vault localization, skull base and orbit localization and facial bone localization. Skull vault bones were parietal bone and frontal or occipital bone but without extension into the skull base portion of these last two bones. Skull base and orbital bones included bone localization forming the skull base and the orbital cavity. Other bone groups were spine, clavicle/sternum/ribs/scapula, pelvis and limb bones. Identification of the BRAF V600E mutation was performed as previously described (H eritier et al, 2016) . This study was approved by the Ethics Committee, Ile de France III (#2011-A00447-34), and conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent to be included in the national histiocytosis registry for a prospective follow-up (Guyot-Goubin et al, 2008; Rigaud et al, 2016) . In this study, cND-LCH was not considered as a reactivation or localization of the active LCH disease.
Statistical analyses
Differences between groups were tested with the MannWhitney U test for quantitative variables and with Fisher's exact test for qualitative variables. Logistic regression analyses were used to estimate the odds of cND-LCH according to involvement of other organs and BRAF status.
Survival analyses included the interval between LCH diagnosis and cND-LCH occurrence. In these analyses, patients were censored at the date of the last examination or death. Survival rates were estimated with the Kaplan-Meier method, and subgroups were compared with the log-rank test. For all statistical analysis, the threshold significance was 0Á05 unless otherwise specified. All statistical analyses were performed with Stata 13 software (StataCorp, College Station, TX, USA). The cut-off date for these analyses was 31 December 2017.
Results
From 1983, the French paediatric LCH cohort comprised 1897 patients, with a median age at diagnosis of 3Á4 years, and a median follow-up of 4Á3 years (range, 0Á1-33Á3 years). In this cohort at the time of the analyses, 65Á3% of patients had SS LCH, 17Á7% of patients had MS ROÀ LCH, 4Á6% had Lung+ LCH and 12Á4% had RO+ MS LCH. The estimated 5-year reactivation rate (RR) for the cohort was 36Á3%, and the estimated 10-year survival rate was 96Á7%.
Among the overall cohort, 36 patients (1Á9%) were diagnosed with a cND-LCH. Median age at the beginning of ND-LCH was 9Á2 years (range, 3Á4-25Á8 years), and the median delay to cND onset was 6Á5 years (range, 0Á4-24Á0 years) after LCH diagnosis. The median incidence of cND-LCH was one per year ( Fig 1A) . The cumulative incidence of cND-LCH in this cohort was 1Á0% (95% confidence interval [CI], 0Á5-1Á7%), 4Á1% (95% CI, 2Á7-5Á9%) and 5Á9% (95% CI, 4Á0-8Á6%) at 5, 10 and 15 years respectively (Fig 1B) .
Most patients presented a combination of neurological dysfunctions that caused significant disability. In decreasing order of importance, symptoms were cerebellar ataxia (n = 28), neurocognitive impairment (n = 25), pyramidal signs (n = 18), pseudobulbar palsy (n = 9) and psychiatric disorders (n = 8). The median follow-up after the beginning of cND-LCH was 10Á5 years (range, 1Á1-27Á7 years). A total of four patients who had pseudobulbar palsy died during the follow-up after the diagnosis of cND-LCH, and the causes of death were directly related to neurological complications of the cND-LCH. Clinical characteristics of each cND-LCH patient are detailed in Table S1 .
Characteristics associated with clinical ND-LCH
The occurrence of a cND-LCH was related to patient characteristics, disease features, and extent of disease (Table I) . Median age at diagnosis for the first LCH manifestation (age at diagnosis) was slightly younger for patients with cND-LCH than for patients without (2Á4 vs. 3Á4 years respectively; P = 0Á02). Of interest, in this paediatric and young adult cohort, no patients with a LCH diagnosis after age 10 years experienced a cND-LCH.
Patients who developed cND-LCH were typically previously treated for a MS ROÀ LCH, representing 69Á4% of such cases vs. 16Á8% of patients without cND-LCH (P < 0Á001). Only one patient (2Á8%) had a SS LCH with pituitary involvement as the sole involved organ before occurrence of the cND-LCH.
LCH with pituitary involvement was significantly associated with occurrence of a cND-LCH: 86Á1% (31/36) of patients with cND-LCH had pituitary involvement compared to 12Á2% (227/1861) of patients without ND (P < 0Á001). Skin involvement also was significantly associated with cND-LCH: 75Á0% of patients with cND-LCH had skin involvement compared to 34Á2% of patients without ND (P < 0Á001). But cND-LCH was not significantly correlated with sex or involvement of the RO (liver, haematological, spleen), lung, lymph nodes or tumourous CNS.
Regarding bone involvement, 30 patients (83Á3%) with a cND-LCH outcome had bone system involvement, but the bone system itself was not associated with cND-LCH (Table I) . However, most of them had a head bone localization (n = 29) and among these, skull vault and skull base or orbit bone localization were more commonly found in patients with cND-LCH compared to patients without (skull vault: 69Á4% vs. 33Á5%, P < 0Á001; skull base or orbit: 63Á9% vs. 28Á4%, P < 0Á001, respectively; Table I ). Skull vault and skull base or orbit bone localizations were frequently associated (occurrence of both localizations, n = 20). It is particularly notable that all patients with cND-LCH in this cohort who did not have skull base or orbit bone localizations had a pituitary involvement (Fig 2) .
Among patients with LCH, 88Á9% with cND-LCH and 43Á9% without cND-LCH were treated for the active LCH disease with a first-line vinblastine-steroid systemic chemotherapy regimen (P < 0Á001). Second-line therapy because of active LCH disease refractory to the vinblastinesteroid therapy was required in 8Á3% of patients with cND-LCH and 7Á1% of patients without cND-LCH (P = 0Á70).
Patients who developed ND had experienced a higher reactivation rate (RR) than those without ND (5-year RR, 75Á0% and 35Á2%, respectively; P < 0Á001; log-rank test). All eight patients who did not experience a reactivation before diagnosis of cND-LCH had pituitary involvement at diagnosis.
Finally, BRAF status was available for 16 patients with cND-LCH. The mutation was positive for 15 cases (93Á7%) compared to 206/381 cases (54Á1%) for ND-free LCH cases (P = 0Á001).
Including the 397 patients of our cohort for whom all clinical and molecular (BRAF V600E status) characteristics were available, we constructed a logistic regression model with cND-LCH as the dependent variable; BRAF V600E status and LCH localizations significantly associated with occurrence of a cND-LCH in the univariate analysis as covariates. In this model (Table II) , the cND-LCH probability was strongly associated with pituitary involvement (odds ratio (OR) = 30Á9, 95% CI: 5Á9-162Á5; P < 0Á001). In addition, BRAF V600E mutation (OR = 9Á8; 95% CI: 1Á2-79Á1; P = 0Á03) was also significantly associated with cND-LCH in this model.
Determination of clinical ND-LCH risk groups
Using Kaplan-Meier survival curves, we estimated the probability of cND-LCH at 10 years in our cohort according to characteristics associated with cND-LCH. pituitary involvement had a higher 10-year cND risk than those without pituitary involvement (10-year cND risk, 13Á2% and 0Á7%, respectively; log-rank test, P < 0Á001; Fig 3A) . Also, patients with BRAF
V600E
-mutated LCH had a higher 10-year cND risk compared to those without BRAF V600E (10-year cND risk, 22Á8% and 1Á3%, respectively; log-rank test; P < 0Á001; Fig 3B) .
As previously mentioned, all cND-LCH patients in our cohort had experienced LCH disease with pituitary or skull base or orbit bone involvement. We observed that patients with one of these conditions (i.e., 'cND susceptible patients' (n = 671) had a 10-year cND risk of 7Á8% (vs. 0% for patients who did not meet one of these criteria (n = 1226), log-rank test, P < 0Á001; Fig 3C) . This group of 'cND susceptible patients' comprised 35Á4% (671/1897) of cases in our cohort.
To determine if BRAF V600E status added discrimination for predicting cND-LCH among patients with these clinical features, we estimated the cumulative cND risk in this selected group of cND susceptible patients (n = 671) according to BRAF mutational status. The 10-year cND risk was estimated at 33Á1% for LCH patients with BRAF V600E compared to 2Á9% for patients without the BRAF V600E mutation (P = 0Á002, log-rank test; Fig 3D) .
Discussion
Our study provides a first estimation of the cumulative incidence of cND-LCH established in a large population-based representative cohort of 1897 LCH patients. In this paediatric and young adult cohort, this reputed incurable late onset sequela had a cumulative incidence of 4Á1% at 10 years (95% CI, 2Á7-5Á9%), and 5Á9% at 15 years (95% CI, 4Á0-8Á6%) (Fig 1B) . Except for these data from our group (The French Langerhans' Cell Histiocytosis Study Group, 1996; Donadieu et al, 2004; Guyot-Goubin et al, 2008; Rigaud et al, 2016 ), a few others exist (Table S2 ) that have included a small cohort of patients and reported an incidence of ND-LCH between 7% and 25% of LCH patients (Nanduri et al, 2003; Haupt et al, 2004; Mittheisz et al, 2007; Imashuku et al, 2008 ; Table I . Characteristics of patients with cND-LCH (n = 36) compared to patients without cND included in the French LCH Registry from 1983 to 2017 (n = 1861).
Characteristic cND-LCH cases, % n = 36 cND-free LCH cases, % n = 1861 P value Wnorowski et al, 2008; Laurencikas et al, 2011) . Considering the size of our cohort, which is based on nationwide multicentric inclusion in a long-standing well-structured network of onco-paediatrician and pathologist practices (The French Langerhans' Cell Histiocytosis Study Group, 1996; H eritier et al, 2016; Rigaud et al, 2016) , our estimation appears to be a fair and unbiased representation of the incidence rate of this complication in LCH. However, some patients with very subtle symptoms of cND-LCH may not have been reported to the registry. Moreover, because patients without reactivation and/or sequelae were usually released for a systematic follow-up between 3 and 5 years after diagnosis unless new symptoms occurred, those patients had a shorter follow-up, leading to a moderately overestimated cumulative incidence of cND-LCH with the Kaplan-Meier method. For this reason, in a second analysis ( Figure S1 ) to address this follow-up heterogeneity, we also estimated the cumulative incidence of cND-LCH with patients censored at the cut-off date (31 December 2017) instead of the last examination. In this second analysis, the cumulative incidence of cND-LCH was 2Á0% (95% CI, 1Á4-2Á9%) and 2Á6% (95% CI, 1Á8-3Á6%) at 10 and 15 years, respectively. Thus, considering these two analyses, we determined the 15-year cumulative incidence of cND-LCH to be between 1Á8% and 8Á6% in this cohort (considering a 95% CI). Also, it should be pointed out that this study concerned only cND-LCH and did not include radiological ND-LCH without clinical symptoms because systematic imaging was not performed in our cohort. As a comparison, Wnorowski et al (2008) reported that 25% of patients with radiological ND-LCH (rND-LCH) would develop clinical cND-LCH. More studies are needed determine the exact prevalence of rND-LCH and the clinical long-term outcome of this imaging finding. Furthermore, a systematic consultation 15 years after a diagnosis with a neurocognitive evaluation would be useful to better specify the cumulative incidence of cND-LCH, although difficulties regarding patient adherence to this much-delayed visit should be anticipated.
In addition to an unbiased estimation of the incidence rate of this complication, our study offers a first analysis of the risk factor of ND in LCH that takes BRAF status into consideration. Previous studies have tried to identify risk factors for ND-LCH. Because ND-LCH is a late complication, some authors have studied the risk of DI secondary to pituitary involvement rather than the risk of ND-LCH directly (Grois et al, 2006) . First, DI secondary to pituitary involvement is associated with ND, so about 70 to 90% of ND-LCH have DI (Donadieu et al, 2004; Grois et al, 2004; Haupt et al, 2004; Mittheisz et al, 2007; Wnorowski et al, 2008) . We previously reported a 15-year cumulative incidence of cND-LCH for patients with DI at 11% compared to below 1% for patients without DI (Donadieu et al, 2004) . Second, previous studies have shown a statistical association between head bone localizations of LCH and occurrence of DI (Donadieu et al, 2004; Haupt et al, 2004; Grois et al, 2006) . By extension, these bone localizations have been considered as 'CNS risk lesions' based on the assumption that DI is a surrogate marker of ND-LCH (Grois et al, 2010) . Among the four studies that have addressed this question, two considered all skull bones together (Donadieu et al, 2004; Haupt et al, 2004) , while two studies evaluated these bones separately with individualization of a group of craniofacial bones that encompassed bones forming the skull base and the orbital cavity, which were associated significantly with DI occurrence (Grois et al, 2006 (Grois et al, , 2010 . Subsequently, skull vault bones were excluded from the definition of 'CNS risk lesions' (Haupt et al, 2013) . Also, the association of pneumothorax and sclerosing cholangitis with DI was found in one study (Donadieu et al, 2004) but not evaluated in others.
Our study allows consideration of BRAF V600E mutation, in addition to other risk factors, as offering the possibility of better defining a cND-LCH risk group. We thus defined a group of 'cND susceptible patients' who made up 35Á4% of our global cohort and encompassed all cND-LCH patients. This Cumulative incidence of cND-LCH among 'cND susceptible patients' (n = 671). In this study, 'cND susceptible patients' were children who had experienced Langerhans cell histiocytosis (LCH) disease with pituitary or skull base or orbit bone involvement. (D) Cumulative incidence of cND-LCH among the selected group of 'cND susceptible patients' according to BRAF V600E mutational status. In this study, 'cND susceptible patients' were children who had experienced LCH disease with pituitary or skull base or orbit bone involvement. In each graph, the vertical dashed line indicates the percentages of clinical ND-LCH observed in each group at 10 years. In graphs B and D, which represent the cND risk according to BRAF V600E mutational status, the light grey dotted line represents patients whose mutation status is unknown and is not involved in the statistical analysis. ND-LCH, neurodegenerative Langerhans cell histiocytosis.[Colour figure can be viewed at wileyonlinelibrary.com] group comprised children who had experienced LCH disease with pituitary or skull base or orbit bone involvement. This group had a 10-year cND risk of 7Á8%, and we showed that molecular BRAF V600E status provides an additional factor for better identifying the risk population (P = 0Á002). One limitation of this study is that BRAF V600E status was not investigated for all patients, especially for all cND-LCH patients because of unavailability of biopsy samples. Also, we did not investigate genotypes more fully among patients with cND-LCH who lacked BRAF V600E (one patient in our study).
Thus, we recommend investigating BRAF V600E molecular status for all patients with clinical risk factors for cND-LCH, and future thorough molecular LCH studies should focus on the rare cND-LCH patients without the BRAF V600E mutation.
A better and reliable identification of the cND-LCH risk population could be of major importance for initiating specific interventions very early in the course of the disease, specifically for at-risk patients, to develop a tailored screening that combines imaging and neurocognitive assessment. Several therapeutic approaches have been attempted in ND-LCH, including retinoic acid (Idbaih et al, 2004) , the combination of vincristine and cytarabine (Allen et al, 2010) , and immunoglobulin (Imashuku et al, 2015) , and the best result that can be expected from such regimens is a stabilization of neurological symptoms. Recently, targeted therapies with BRAF inhibitors have shown efficacy in active BRAF V600E -mutated LCH and represent a promising approach (Haroche et al, 2013; H eritier et al, 2015) . In ND-LCH, little is known about clinical efficacy with BRAF-targeting therapies. More recently, BRAF inhibitors showed efficacy in a ND mouse model induced by the expression of BRAF V600E in microglia with shared key histological, cellular and molecular features observed in cND-LCH. Of importance, efficacy was better when the treatment was initiated early and may prevent ND lesions (Mass et al, 2017) . These data emphasise that future clinical trials should evaluate a cND-risk based screening with imaging and neurocognitive assessment for a defined LCH patient group and evaluate the benefits of BRAF inhibitor treatment in the early stages of cDN-LCH.
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